Evidence map›Paper›PMID 23608036›Full record

ReviewTrends in microbiology2013

Potential of protein kinase inhibitors for treating herpesvirus-associated disease.

Renfeng Li, S Diane Hayward

Open access · greenAbstract readReview
In one paragraph

Review in Trends in microbiology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 23 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Recent Advances in Protein Kinase Activity Analysis Based on Nanomaterials.International journal of molecular sciences · 2019
    Review
  10. Novel Therapeutics for Epstein⁻Barr Virus.Molecules (Basel, Switzerland) · 2019
    Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Renfeng LiViral Oncology Program, Department of Oncology, Johns Hopkins School of Medicine, Baltimore, MD 21287, USA. rli13@jhmi.edu
S Diane Hayward
Johns Hopkins Medicine · USJohns Hopkins University · US

Funding

Herpesvirus protein kinases: Substrate recognition and pathway targeting.R21AI101377 · NIAID · JOHNS HOPKINS UNIVERSITY · PI HAYWARD, S DIANE · 2012 to 2013
$433k
Impact of herpesvirus protein kinases on host protein modificationK99AI104828 · NIAID · JOHNS HOPKINS UNIVERSITY · PI LI, RENFENG · 2013 to 2013
$85k
NIAID NIH HHS K99 AI104828NIAID NIH HHS R21 AI101377NIAID NIH HHS R21AI101377
6 · The paper itself

Abstract

Herpesviruses are ubiquitous human pathogens that establish lifelong persistent infections. Clinical manifestations range from mild self-limiting outbreaks such as childhood rashes and cold sores to the more severe and life-threatening outcomes of disseminated infection, encephalitis, and cancer. Nucleoside analog drugs that target viral DNA replication provide the primary means of treatment. However, extended use of these drugs can result in selection for drug-resistant strains, particularly in immunocompromised patients. In this review we will present recent observations about the participation of cellular protein kinases in herpesvirus biology and discuss the potential for targeting these protein kinases as well as the herpesvirus-encoded protein kinases as an anti-herpesvirus therapeutic strategy.

Indexed as

Antiviral AgentsClinical Trials as TopicHerpesviridaeHerpesviridae InfectionsHumansProtein Kinase InhibitorsTreatment OutcomeVirus ReplicationAntiviral AgentsProtein Kinase Inhibitors

Identifiers

PMID23608036
PMCPMC3674143
OpenAlexW1986456835

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.